nach oben

Erschienen in:

01.07.2012 | Preclinical study

Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter

verfasst von: V. Bartella, P. Rizza, I. Barone, D. Zito, F. Giordano, C. Giordano, S. Catalano, L. Mauro, D. Sisci, M. L. Panno, S. A. W. Fuqua, S. Andò

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Human estrogen receptors alpha and beta are crucially involved in the regulation of mammary growth and development. Normal breast tissues display a relative higher expression of ER beta than ER alpha, which drastically changes during breast tumorogenesis. Thus, it is reasonable to suggest that a dysregulation of the two estrogen receptor subtypes may induce breast cancer development. However, the molecular mechanisms underlying the potential opposing roles played by the two estrogen receptors on tumor cell growth remain to be elucidated. In the present study, we have demonstrated that ER beta overexpression in breast cancer cells decreases cell proliferation and down-regulates ER alpha mRNA and protein content, along with a concomitant repression of estrogen-regulated genes. Transient transfection experiments, using a vector containing the human ER alpha promoter region, showed that elevated levels of ER beta down-regulated basal ER alpha promoter activity. Furthermore, site-directed mutagenesis and deletion analysis revealed that the proximal GC-rich motifs at −223 and −214 are critical for the ER beta-induced ER alpha down-regulation in breast cancer cells. This occurred through ER beta-Sp1 protein–protein interactions within the ER alpha promoter region and the recruitment of a corepressor complex containing the nuclear receptor corepressor NCoR, accompanied by hypoacetylation of histone H4 and displacement of RNA-polymerase II. Silencing of NCoR gene expression by RNA interference reversed the down-regulatory effects of ER beta on ER alpha gene expression and cell proliferation. Our results provide evidence for a novel mechanism by which overexpression of ER beta through NCoR is able to down regulate ER alpha gene expression, thus blocking ER alpha’s driving role on breast cancer cell growth.

Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276:36869–36872PubMedCrossRef

Heldring N, Pike A, Andersson S et al (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905–931PubMedCrossRef

Osborne CK, Schiff R, Fuqua SA et al (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7:4338s–4342s (discussion 4411s–4412s)PubMed

Barone I, Brusco L, Fuqua SA (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16:2702–2708 ReviewPubMedCrossRef

Cato AC, Nestl A, Mink S (2002) Rapid actions of steroid receptors in cellular signaling pathways. Science STKE 138:re9

Nemere I, Pietras RJ, Blackmore PF (2003) Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 88:438–445PubMedCrossRef

Ordonez-Moran P, Munoz A (2009) Nuclear receptors: genomic and nongenomic effects converge. Cell Cycle 8:1675–1680PubMedCrossRef

Paech K, Webb P, Kuiper GG et al (1997) Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508–1510PubMedCrossRef

Webb P, Nguyen P, Valentine C et al (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13:1672–1685PubMedCrossRef

10.

Kushner PJ, Agard DA, Greene GL et al (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311–317PubMedCrossRef

11.

Salvatori L, Pallante P, Ravenna L et al (2003) Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER α and β subtypes via an Sp1 site. Oncogene 22:4875–4881PubMedCrossRef

12.

Safe S, Kim K (2004) Nuclear receptor-mediated transactivation through interaction with Sp proteins. Nucleic Acid Res Mol Biol 77:1–36CrossRef

13.

Panno ML, Mauro L, Marsico S et al (2006) Evidence that mouse IRS-1 belongs to the family gene which promoter is activated by ERα through its interaction with Sp-1. J Mol Endocrinol 36:91–105PubMedCrossRef

14.

Catalano S, Rizza P, Gu G et al (2007) Fas ligand expression in TM4 Sertoli cells is enhanced by estradiol in situ production. J Cell Physiol 211:448–456PubMedCrossRef

15.

Mauro L, Catalano S, Bossi G et al (2007) Evidences that leptin upregulates E-cadherin expression in breast cancer effects on tumor growth and progression. Cancer Res 67:3412–3421PubMedCrossRef

16.

Higgins KJ, Shengxi L, Abdelrahim M et al (2008) Vascular endothelial growth factor receptor-2 expression is down-regulated by 17 beta estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp-1 proteins. Mol Endocrinol 22:388–402PubMedCrossRef

17.

Varlakhanova N, Snyder C, Jose S et al (2010) Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol Cell Biol 30:1434–1445PubMedCrossRef

18.

Allegra JC, Lippman ME, Green L et al (1979) Estrogen receptor values in patients with benign breast disease. Cancer 44:228–231PubMedCrossRef

19.

Petersen OW, Hoyer PE, van Deurs B (1987) Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 47:5748–5751PubMed

20.

Ricketts D, Turnbull L, Ryall G et al (1991) Estrogen and progesterone receptors in the normal female breast. Cancer Res 51:1817–1822PubMed

21.

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282PubMedCrossRef

22.

Zhao C, Dahlman-Wright K et al (2008) Estrogen receptor beta: an overview and update. Nucl Recept Signal 6:e003PubMed

23.

Skliris GP, Munot K, Bell SM et al (2003) Reduced expression of estrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201:213–220PubMedCrossRef

24.

Hopp TA, Weiss HL, Parra IS et al (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10:7490–7499PubMedCrossRef

25.

Paruthiyil S, Parmar H, Kerekatte V et al (2004) Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 Cell Cycle Arrest. Cancer Res 64:423–428PubMedCrossRef

26.

Chang EC, Frasor J, Komm B et al (2006) Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology 147:4831–4842PubMedCrossRef

27.

Williams C, Edvardsson K, Lewandowski SA et al (2008) A genome-wide study of repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27:1019–1032PubMedCrossRef

28.

Ström A, Hartman J, Foster JS et al (2004) Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci 101:1566–1571PubMedCrossRef

29.

Hartman J, Lindberg K, Morani A et al (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66:11207–11213PubMedCrossRef

30.

Saji S, Omoto Y, Shimizu C et al (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853PubMed

31.

Buteau-Lozano H, Ancelin M, Lardeux B et al (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and β. Cancer Res 62:4977–4984PubMed

32.

Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y et al (2003) Estrogen receptor (ER) β1 and ERβcx/β ERα function differently in breast cancer cell line MCF7. Oncogene 22:5011–5020PubMedCrossRef

33.

Pettersson K, Delaunay F, Gustafsson JA (2000) Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19:4970–4978PubMedCrossRef

34.

Nilsson S, Makela S, Treuter E et al (2001) Mechanisms of estrogen action. Physiol Rev 81:1535–1565PubMed

35.

Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277:24353–24360PubMedCrossRef

36.

Acconcia F, Totta P, Ogawa S et al (2005) Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling. J Cell Physiol 203:193–201PubMedCrossRef

37.

deGraffenried LA, Hopp TA, Valente AJ et al (2004) Regulation of the estrogen receptor α minimal promoter by Sp1, USF-1 and ERα. Breast Cancer Res and Treat 85:111–120CrossRef

38.

Catalano S, Malivindi R, Giordano C et al (2010) Farnesoid X Receptor through its binding to Steroidogenic Factor 1 responsive element inhibits aromatase expression in tumor Leydig cells. J Biol Chem 285:5581–5593PubMedCrossRef

39.

Andrews NC, Faller DV (1991) A rapid microperation technique foe extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499PubMedCrossRef

40.

Barone I, Cui Y, Herynk MH et al (2009) Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3 K/Akt kinase pathway. Cancer Res 69:4724–4732PubMedCrossRef

41.

Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454–457PubMedCrossRef

42.

Zamir I, Dawson J, Lavinsky RM et al (1997) Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex. Proc Natl Acad Sci USA 94:14400–14405PubMedCrossRef

43.

Huynh KD, Fischle W, Verdin E et al (2000) BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 14:1810–1823PubMed

44.

Lee JA, Suh DC, Kang JE et al (2005) Transcriptional activity of Sp1 is regulated by molecular interactions between the zinc finger DNA binding domain and the inhibitory domain with corepressors, and this interaction is modulated by MEK. J Biol Chem 280:28061–28071PubMedCrossRef

45.

Panno ML, Salerno M, Pezzi V et al (1996) Effect of estradiol and insulin on proliferative pattern and on estrogen and progesterone receptor contents in MCF-7 cells. J Cancer Res Clin Oncol 122:745–749PubMedCrossRef

46.

Lee AV, Weng C-N, Jackson JG et al (1997) Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152:39–47PubMedCrossRef

47.

Andò S, Panno ML, Salerno M et al (1998) Role of IRS-1 signaling in insulin-induced modulation of estrogen receptors in breast cancer cells. Biochem Biophys Res Commun 253:315–319PubMedCrossRef

48.

Lannigan DA (2003) Estrogen receptor phosphorylation. Steroids 68:1–9PubMedCrossRef

49.

Leygue E, Dotzlaw H, Watson PH et al (1998) Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res 58:3197–3201PubMed

50.

Jarvinen TA, Pelto-Huikko M, Holli K et al (2000) Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156:29–35PubMedCrossRef

51.

Roger P, Sahla ME, Makela S et al (2001) Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed

52.

Fixemer T, Remberger K, Bonkhoff H (2003) Differential expression of the estrogen receptor beta in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54:79–87PubMedCrossRef

53.

Foley EF, Jazaeri AA, Shupnik MA et al (2000) Selective loss of estrogen receptor β in malignant human colon. Cancer Res 60:245–248PubMed

54.

Pujol P, Rey JM, Nirde P et al (1998) Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367–5373PubMed

55.

Behrens D, Gill JH, Fichtner I (2007) Loss of tumourigenicity of stably ERβ-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 274:19–29PubMedCrossRef

56.

Song K, Pan ZZ (2012) Estrogen receptor beta agonist diarylpropionitrile counteracts the estrogenic activity of estrogen receptor alpha agonist propylpyrazole-triol in the mammary gland of ovariectomized Sprague Dawley rats. J Steroid Biochem Mol Biol 130:26–35PubMedCrossRef

57.

Mann S, Laucirica R, Carlson N et al (2001) Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32:113–118PubMedCrossRef

58.

Murphy LC, Leygue E, Niu Y et al (2002) Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 87:1411–1416PubMedCrossRef

59.

Esslimani-Sahla M, Simony-Lafontaine J, Kramar A et al (2004) Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769–5776PubMedCrossRef

60.

Saville B, Wormke M, Wang F et al (2000) Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275:5379–5387PubMedCrossRef

61.

Porter W, Saville B, Hoivik D et al (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11:1569–1580PubMedCrossRef

62.

Duan R, Porter W, Safe S (1998) Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139:1981–1990PubMedCrossRef

63.

Vyhlidal C, Samudio I, Kladde MP et al (2000) Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response half-site. J Mol Endocrinol 24:329–338PubMedCrossRef

64.

Nagy L, Kao HY, Chakravarti D et al (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373–380PubMedCrossRef

65.

Hu X, Lazar MA (1999) The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93–96PubMedCrossRef

66.

Webb P, Anderson CM, Valentine C et al (2000) The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Mol Endocrinol 14:1976–1985PubMedCrossRef

67.

Jiang S, Meyer R, Kang K et al (2006) Scaffold attachment factor SAFB1 suppresses estrogen receptor α-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol 20:311–320PubMedCrossRef

68.

De Amicis F, Zupo S, Panno ML et al (2009) Progesterone receptor B recruits a repressor complex to a half-TRE site of the estrogen receptor α gene promoter. Mol Endocrinol 23:454–465PubMedCrossRef

69.

Ghisletti S, Huang W, Jepsen K et al (2009) Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Gene Dev 23:681–693PubMedCrossRef

Titel: Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter
verfasst von: V. Bartella
P. Rizza
I. Barone
D. Zito
F. Giordano
C. Giordano
S. Catalano
L. Mauro
D. Sisci
M. L. Panno
S. A. W. Fuqua
S. Andò
Publikationsdatum: 01.07.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2090-9

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Springer Medizin

Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer

Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie